Nkarta Q2 net loss $25M; cash $426.7M; NKX019 autoimmune trial Ntrust-2 to start by year-end

Nkarta, Inc.

2024-Q2 EPS reported -$0.88

Net loss of $25.0M ($0.34 diluted EPS); R&D expense $23.1M, G&A $7.6M.
Cash & investments $426.7M expected to fund operations into late 2027.
FDA cleared second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment for systemic sclerosis, myositis, vasculitis expected by year-end 2024.
Preliminary Ntrust-1 and Ntrust-2 data planned for 2025; NHL 7-day dosing cohort enrollment completed, data due late 2024.
Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.